Monday, 8 June 2020

Acoustic Neuroma Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020 - 2023

The global acoustic neuroma treatment market is expected to grow at a CAGR of approximately 7.6% during the forecast period 2017-2023.
Market Scenario
Acoustic neuromas also known as vestibular schwannomas, usually grows slowly over a period of years. Usually they do not invade the brain, but can push on it as they grow. As the tumor grows, they press the nearby cranial nerves that control the muscles enabling facial expression and sensation. If the tumor becomes large enough to press on the brain stem or cerebellum, it can be deadly. They account for almost 8% of all tumors inside the skull. The prevalence rate is 1 out of every 100,000 individuals per year.
An acoustic neuroma is a non-cancerous (benign) growth that develops on the 8th cranial nerve (vestibulocochlear nerve), it connects the inner ear with the brain and has two different parts. One part is involved in transmitting sound and the other sends balance information to the brain.
Acoustic neuromas are mainly categorized into unilateral and bilateral vestibular schwannomas. Unilateral affect only one ear and bilateral vestibular schwannomas affect both hearing nerves and are usually associated with some genetic disorder. More than half of the affected individuals have inherited the disorder from an affected parent. Several new drugs are launched by the key players which grants various opportunities for the global acoustic neuroma market.
Usually these neuromas are rare. Globally around 1-20 people in every million are diagnosed each year with an acoustic neuroma. Acoustic neuromas account for about 6 cases in every 100 patients with brain tumours. They are more common in middle-aged adults and are rare in children. Furthermore,  these neuromas seem to be more common in women than in men. Acoustic neuromas tend to affect adults aged 30 to 60 and usually have no obvious cause, although a small number of cases are the result of a genetic condition called neurofibromatosis type 2 (NF2).
The gadolinium enhanced magnetic resonance imaging (MRI) is the gold standard for diagnosis of vestibular schwannoma yet several examinations may arise suspicion of vestibular schwannomas. According to a patient survey held by the Acoustic Neuroma Association, in 2012, it was reported that after surgical treatment of acoustic neuroma more than 35% patients suffered a headache depending on the type of surgical approach, technique used and the time since surgery.
Top Key Acquisitions
Many new companies have jumped into the market in order to make the most out of the opportunities. Companies are implementing the strategies of mergers and acquisitions with other players.
Some of key the players in the global acoustic neuroma market are GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), F. Hoffmann-La Roche Ag, Merck & Co., Inc., Novartis AG, Pfizer Inc., and others
Segmentation
The acoustic neuroma is segmented on the basis of type, diagnosis, drug class, treatment, and end-users.
On the basis of type, the market is segmented into unilateral vestibular schwannomas and bilateral vestibular schwannomas.
On the basis of diagnosis, the market is segmented into hearing test (audiometry), electronystagmography, magnetic resonance imaging (MRI), and others.
On the basis of end-user, the market is segmented into hospitals, diagnostic centers, academic and research institutes, and others.
On the basis of drug class, the market is segmented into anticonvulsants, corticosteroids, osmotic diuretics and pain killers.
On the basis of treatment, the market is segmented into monitoring, surgery, radiation therapy, supportive therapy and others. The radiation therapy is sub segmented stereotactic radiotherapy, proton beam therapy. Surgery is sub segmented radiosurgery, craniotomy, and microsurgery removal
Regional Analysis
The global acoustic neuroma market consists of countries namely America, Europe, Asia Pacific, and the Middle East.
North America is projected to hold the largest share of the global acoustic neuroma market due to presence of huge numbers of key players supporting research and development for developing novel therapies, large base of diagnostic centers and greater emphasis on disease prevention and wellness by governments. Along with that healthcare facilities in the U.S. are gradually moving from treatment to wellness, so the prevention and early detection of disease is critical. Approximately 2,000 to 3,000 cases are diagnosed each year with acoustic neuroma in the United States (6 to 9 per million persons).
The European acoustic neuroma market hold the second largest market as it witness rapid growth. According to NHS U.K, an acoustic neuroma can occasionally return after treatment. This is thought to happen to around 1 in every 20 people who have had surgical removal.
Asia Pacific is expected to be the most promising markets for acoustic neuroma in the near future The Middle Eastern region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Silent Heart Attack Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2023

Market Synopsis of the Global Silent Heart Attack Market
The market is driven by upcoming silent heart attack market trends and rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.
The global silent heart attack market is expected to grow at a CAGR of 5.7% during the forecast period.
According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.
Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.
Segments                                                                                                                                            
The global silent heart attack market is segmented on the basis of diagnosis, indication, devices, and end user.
On the basis of diagnosis, market is segmented into cardiac computerized tomography, magnetic resonance imaging, electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, coronary artery bypass surgery, and others.
On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Key Players in the Global Silent Heart Attack Market   
Some of the key players in this market are Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland).
Regional Analysis of the Global Silent Heart Attack Market                 
America accounts for the largest market for the silent heart attack. Increasing prevalence of cardiovascular diseases, and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the market.
Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.
In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.
Top 5 Reasons to Get this Report:
Company profiling with detailed strategies, financials, and recent development activities
Market Strategic Business Influence Data
Market Research Future recommendations in key business segments based on the market estimations
Market share analysis of the top industry players
Market forecasts for a minimum of 5 years of all the mentioned segments, Trends and the regional markets With SWOT Analysis

Drug Allergy Market 2020 Global Overview, Regional Analysis, Size, Share and Forecast to 2023

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Key Players
MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 

Global Anti-viral drugs Market 2020 – Investment Strategy, Outlook and Key Development till 2023

Market Scenario:
The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.
The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug market growth.
The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.
However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period. 
Key Players
MRFR have enlisted some of the prominent Anti-viral drugs Market Companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 
Market Segmentation:
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Regional Analysis:
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market. 

Bioinformatics Market 2020 Global Trend, Segmentation and Opportunities, Forecast 2023

Market scenario:
The Global Bioinformatics Market report from Market Research Future (MRFR) is expected to exhibit a CAGR of 19.8% over the forecast period from 2016 to 2022, according to a new research. The global bioinformatics trends and industry is mainly driven by the growing demand in developing countries in enhancing their healthcare sector and making advanced healthcare modalities available to patients.
The growing demand for electronic healthcare data storage is likely to be a major driver for the global bioinformatics market. The reliance on manual and paper-based documentation of healthcare procedures has resulted in unmanageable volumes of healthcare information, which can make it difficult to locate individual patients and their medical history. Electronic healthcare records, which are but the first step of the bioinformatics market, have already become widely popular in developed countries due to the benefits they present in terms of consistent data storage over the long term and ease in acquiring specific details at any given time. The growing demand for e-prescriptions and online pharmacies is likely to further the cause of the bioinformatics market over the forecast period, as strong bioinformatics networks are needed to operate and manage e-prescriptions and the related documentation.
The growing demand for strong data storage facilities in medical research is also likely to be a major driver for the global bioinformatics market. Bioinformatics plays a key role in genetic studies, in which it helps track details regarding multiple genes and their multifarious associations with the indicators being studied in the respective trial. The growing dependence on genetic studies in cancer research is likely to be a major driver for the global bioinformatics market over the forecast period, as cancer research has received strong government backing across the world. Other medical research applications are also likely to make use of bioinformatics systems on a large scale in the coming years, leading to steady growth of the global bioinformatics market over the forecast period.
Study Objectives of Bioinformatics Market:
  • To provide detail analysis of the market structure along with forecast for the next 7 years about various segments and sub-segments of the global bioinformatics market.
  • To provide insights about factors affecting the market growth.
  • To analyze the market based on price analysis, supply chain analysis, Porters Five Force analysis etc.
  • To provide past and estimated future revenue of the market’s  segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
  • To provide country level analysis of the market with respect to the current market size and future growth prospective.
  • To provide country level analysis of the market for segments by drug application, by technology, by sector and services and its sub-segments.
  • To provide overview about key players and their strategic profiling in the market; comprehensively analyzing their core competencies and drawing a competitive landscape of the market.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Bioinformatics market.
Intended Audience
  • Bioinformatics service providers
  • Bioinformatics manufacturers
  • Research and development (R&D) companies
  • Government research laboratories
  • Government and independent regulatory authorities
Segmentation:
The global bioinformatics market is segmented on the basis of application, service, sector, and region in the MRFR report in order to provide a comprehensive coverage of all important factors related to the market’s growth prospects over the forecast period.
The bioinformatics market has been segmented on the basis of application into genomics, chemoinformatics, drug design, transcriptomics, molecular phylogenetics, proteomics, metabolomics, DNA sequences, and others. Increasing interest in genetic studies is likely to be a major driver for the global bioinformatics market over the forecast period.
On the basis of services and technology, the global bioinformatics market is segmented into data warehousing, sequence analysis, sequence manipulation, and others.
Key Players for Bioinformatics Market:                                                        
  • Agilent Technologies,
  • Illumina, Inc.,
  • QIAGEN N. V, and Thermo Fisher Scientific Inc.,
  • Dassault Systèmes,
  • QIAGEN and others.   
Regional Analysis:
The global bioinformatics market is segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa. The global bioinformatics market is dominated by the Americas and Europe in terms of region due to the presence of strong telecommunications infrastructure in these regions to support advanced bioinformatics processes. The presence of a strong wireless internet and other telecommunication features is crucial for a bioinformatics system to function productively. This has actually been one of the key factors that has held back the bioinformatics market in underdeveloped regions.
In April 2019, researchers from UCLA announced a plan to develop a system that would allow scientists in developing countries to use cloud computing and big data analytics to accelerate the development of the bioinformatics field in their own countries. Efforts such as these are the result of the growing awareness of the disparity in terms of telecommunications infrastructure between developed and developing countries.
Asia Pacific is likely to exhibit the fastest growth over the forecast period due to the increasing efforts from governments in the region to incorporate powerful bioinformatics programs into the day-to-day functioning of their country’s healthcare sector.

Sunday, 7 June 2020

Global Microbiology Testing Market 2020 Business Insights & Deep Analysis to 2023 by World’s Top 10 Key Players

Overview

The Global Microbiology Testing Market Size is expected to register 10.4% CAGR and is anticipated to reach USD 5409.1 6 Million by 2023. Microbiology testing services help to lower the potential damage risk by microbes and to ensure that the microbiology quality of the products is maintained. The microbial testing technique includes chemical, biological, biochemical, or molecular methods to quantify and identify microbes.
Technological advancements, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are the major drivers propelling market growth. However, erroneous results and high cost of reagents and instruments may constrain the growth of the market.
Market Dynamics
Technological advancements are expected to drive the growth of the market. For instance, according to the data published by the National Centre for Health Statistics in 2017, there were around 9,272 cases of tuberculosis infectious disease. Additionally, rising cases of infectious diseases, surveillance programs for disease control, increasing stringency of standards, weakness of traditional laboratory techniques are likely to support market growth. On the other hand, erroneous results and high cost of reagents and instruments are anticipated to hamper the market growth.
Segmentation
The global market has been segmented into product type, application, and end user. 
Based on type, the global market has been segmented into instruments, chemicals & reagents, consumables & accessories, and others. The instruments segment accounted for a market value of USD 954.9 million in 2016.
Based on application, the global market has been segmented into gastrointestinal infections, respiratory infections, urinary tract infections, sexually transmitted infections, and others.
Based on end user, the global market has been segmented into hospital associate laboratory, independent laboratory, and academic and research institutes.
Key Players
The prominent players in the global microbiology testing market are, Beckman Coulter, Inc. (a subsidiary of Danaher Corp), BioMérieux SA, Thermo Fisher Scientific Inc., Cepheid (a subsidiary of Danaher), and F. Hoffmann-La Roche Ltd.
Some of the key strategies followed by the players operating in the global microbiology testing market were innovation, product development, acquisition, and expansion.
Regional Analysis
The global microbiology testing market, based on region, is segmented into North Americas, Europe, Asia-Pacific, and the Middle East & Africa.
North America is estimated to dominate the global microbiology testing market during the forecast period. This can be attributed to the rapid adoption of advanced products and techniques. The European market for microbiology testing is expected to be the second-largest during the forecast period. Increasing innovation and changing laboratory practices is expected to boost the growth of the market in this region.
Asia-Pacific is estimated to be the fastest-growing market due to increasing funding for R&D, developing healthcare infrastructure, growing awareness about microbiology testing, government initiatives to improve public health, and growing investments by major players. Moreover, in the region, South Korea accounted for a market share of 9.2% in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to limited access to healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, and limited availability to equipment.

Dental Consumables Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2024

Market Scenario:
Acknowledging the developments and accruals the market is enjoying currently, Market Research Future (MRFR) in its recently published study report asserts that the global dental consumables market will be valued at USD 28,345 MN by 2024, registering approximately 7 % CAGR during the forecast period (2016 – 2024). 
The global market of dental consumables, including US dental consumables market is growing pervasively mainly due to the technological advancements that took place in the dental industry. Although the integration of technology & consumables in dental practices goes back to decades, the uptake of consumables has been increasing over the past few years, and so is increasing the growth of the dental consumables market. Furthermore, factors such as the wide adoption of dental consumables along with the increasing geriatric populace, prevailing dental disorders and surgeries are driving the market growth.
The growing spread of the dentistry field has been a massive driver for the global dental consumables market over the forecast period. The field of dentistry has evolved rapidly in modern times to encompass several specialties such as orthodontics, prosthodontics, and endodontics. This has led to a growing demand for a number of procedures in the dentistry field as well as for the consumables used in these procedures. The rapid evolution of the dentistry field is likely to remain a major driver for the global dental consumables market over the forecast period. The growing insistence on single-use consumables, in order to ensure the sterility and safety of the component in each procedure, is also likely to drive the demand from the dental consumables market over the forecast period. While the field of dentistry has grown to encompass several sub-specialties, the instruments and equipment used by the various fields are largely similar, leading to a steady growth in demand from the dental consumables market.
The growing demand for dental procedures due to the growing prevalence of conditions such as plaque and dental caries is likely to remain a major driver for the global dental consumables market over the forecast period. Growing consumption of chocolate and candy among the younger generation has led to a growing prevalence of dental problems around the world, leading to a growing demand for dental procedures and thus for dental consumables. The growing disposable income of consumers in emerging regions is also likely to be a key driver for the global dental consumables market over the forecast period.
On the other hand, these dental consumables are costlier especially in developing and underdeveloped nations which in turn, is hampering the market growth in these regions restricting the uptake of consumables. Also, the operational complexities of these consumables may restrain the growth of this market.
Competitive Analysis:
Leading players in the global dental consumables market include Septodont, Straumann, KERR Corporation, EnvisionTEC, American Orthodontics, Dentsply Sirona, Nobel Biocare, Planmeca OY, Patterson Dental, GC Orthodontics, Henry Schein, and 3M.
In March 2019, the NHS announced a planned price increase for dental procedures from April 1. The price increase covers minor dental procedures as well as major operations such as root canal. This could have a key impact on the dental consumables market in Europe over the forecast period.
Segmentation:
The global dental consumables market is segmented on the basis of type and region.
By type, the global dental consumables market is segmented into dental implants, dental restorative materials, dental prosthetics, dental regenerative materials, and others. The dental implants segment is likely to remain the top earner in the global dental consumables market over the forecast period due to the growing demand for dental implants for health as well as cosmetic reasons.
Regional Analysis:
The global dental consumables market is segmented by region into Americas, Europe, Asia Pacific, and the Middle East and Africa.
Europe holds the largest share in the global dental consumables market by region and is likely to remain the leading revenue generator in the market over the forecast period due to the growing demand for advanced dental procedures in the region and the widespread availability of dental healthcare facilities. The growing scope of the healthcare sector in the region is likely to enable smooth growth of the dental consumables market over the forecast period.
Asia Pacific is likely to exhibit the fastest growth in the global dental consumables market over the forecast period due to the growing disposable income of consumers in the region and the growing prevalence of dental conditions requiring complicated operations and surgical procedures.
The Americas is also likely to hold on to a major share in the global dental consumables market due to the strong presence of several leading players in the dental consumables industry and the high spending power of the geriatric demographic in the region, which plays a key role in the growth of dental services and equipment.